Skip to main content
Equibles

Bank of New York Mellon Corp

Bank

Position in AKTS — Aktis Oncology, Inc.

CIK 1390777 NEW YORK, NY
Back to AKTS Full portfolio

Position in AKTS

as of Jun 30, 2026 · filed Aug 6, 2026
Position Value
$1,587,326
+$819,828 QoQ
Shares Held
49,250
+14.8% QoQ
Ownership
0.089%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#40
of 114 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority Sole 94% Shared 0% None 6%

Common Shares in AKTS Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Bank of New York Mellon Corp holds $4,864,365,655 across 311 Biotechnology names. AKTS ranks #170 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 1,672,623 $830,842,010
2 REGN
Regeneron Pharmaceuticals, Inc.
 758,492 $472,950,091
3 JAZZ
Jazz Pharmaceuticals plc
 1,578,013 $380,253,782
4 ALNY
Alnylam Pharmaceuticals, Inc.
 492,071 $148,128,128
5 INSM
INSMED Inc
 1,312,756 $139,966,036
6 MRNA
Moderna, Inc.
 1,701,675 $119,168,293
7 RVMD
Revolution Medicines, Inc.
 601,056 $112,565,759
8 INCY
Incyte Corp
 972,825 $110,279,435

All Filings in AKTS

Export CSV
2 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $1,587,326 49,250
2026-03-31 $767,498 42,901